IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the ...
(PR-inside.com) Canada grants patent on IGC-AD1, an investigational oral therapy for agitation in Alzheimer's disease. Agitation is one of the hardest symptoms for families to manage. POTOMAC, MD / ACCESS Newswire / November 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biote…
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


